Anticoagulation for the intial treatment of venous thromboembolism in patients with cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Akl, Elie A ^a   Rohilla, S ^b   Barba, M ^b   Sperati, F ^b   Terrenato, I ^b   Muti, P ^b   Schunemann H J ^b  

^a ERIE COUNTY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; COUMARIN DERIVATIVE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN; WARFARIN; POLYSACCHARIDE;

ANTICOAGULATION; BLEEDING; CANCER PATIENT; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; META ANALYSIS; NEOPLASM;

ANTICOAGULANTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; POLYSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 41949136069     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006649.pub2     Document Type: Review

References (77)

1. Breddin 2001 {published data only} Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, Cortes Investigators. Clivarin: Assessment of Regression Thrombosis, Efficacy, Safety. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine 2001;344(9):626-31.
2. Columbus 1997 {published data only} Buller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, Baildon R, Ten Cate JW, The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine 1997;337(10):657-62.
3. Duroux 1991 {published data only} Duroux P, Ninet J, Bachet P, Prandoni P, Ruol A, Vigo M, et al.A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosisi. A collaborative Eurpean multicenter study. Thrombosis & Haemostasis 1991;65(3):251-6.
4. Galilei 2004 {published data only} Prandoni P, Carnovali M, Marchiori A, Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine 2004;164(10):1077.
5. Hull 1992 {published data only} Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al.Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine 1992;326(15):975-82.
6. Koopman 1996 {published data only} Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al.Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine 1996;334(11):682-7.
7. Levine 1996 {published data only} Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al.A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine 1996;334(11):677-81.
8. Lindmaker 1994 {published data only} Lindmarker P, Holstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis & Haemostasis 1994;72(2):186- 90.
9. Lopaciuk 1992 {published data only} Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, et al.Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis & Haemostasis 1992;68(1):14-18.
10. Matisse 2003 {published data only} Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F et al Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. New England Journal of Medicine 2003;349:1695-702.
11. Merli 2001 {published data only} Merli G, Spiro TE. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine 2001;134(3):191-202.
12. Prandoni 1992 {published data only} Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M, et al.Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339(8791):441-5.
13. Simmoneau 1993 {published data only} Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, et al.Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Archives of Internal Medicine 1993;153(13):1541-6.
14. Simmoneau 1997 {published data only} Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al.A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. New England Journal of Medicine 1997;337(10):663-9.
15. Wells 2005 {published data only} Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, et al.A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine 2005;165:733-738.
16. Altundag 2005 Altundag K, Altundag O, Atik MA. Heparin and CXCL12 dimerization. Journal Of Clinical Oncology 2005;23(28):7248.
17. Anton 2001 Anton N, Massicotte MP. Venous thromboembolism in pediatrics. Seminars in Vascular Medicine 2001;1(1):111-22.
18. Bauer 2000 Bauer KA. Venous thromboembolism in malignancy. Journal of Clinical Oncology 2000;18(17):3065-7.
19. Bick 2003 Bick RL. Cancer-associated thrombosis. New England Journal of Medicine 2003;349(2):109-11.
20. Booth 1981 Booth BW, Weiss RB. Venous thrombosis during adjuvant chemotherapy. New England Journal of Medicine 1981;305:3.
21. Bratt 1985 Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thrombosis & Haemostasis 1985;54(4):813-7.
22. Brooks 1969 Brooks MB. Heparin in the treatment of hemorrhagic diathesis associated with prostatic carcinoma. Journal of Urology 1969;102(2):240-3.
23. Dolovich 2004 Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Archives of Internal Medicine 2000;160(2):181-8.
24. Douketis 2000 Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine 2000;160(22):3431-6.
25. Eikelboom1998 Eikelboom JW, Baker RI. Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma. American Journal of Hematology 1998;59(3):260-1.
26. Elly 1969 Elly GL. Heparin therapy for bleeding associated with hemangioma. Surgery 1969;65(6):894-7.
27. Gould 1999 Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Annals of Internal Medicine 1999;130(10):800-9.
28. Green 1992 Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992;339(8807):1476.
29. Haage 2002 Haage P, Krings T, Schmitz-Rode T. Nontraumatic vascular emergencies: Imaging and intervention in acute occlusion. European Radiology 2002;12(11):2627-43.
30. Handeland 1990 Handeland GF. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. European Journal of Clinical Pharmacology 1990;39(2):107- 12.
31. Hettiarachchi 1998 Hettiarachchi RJ, Prins MH, Lensing AW, Buller HR. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Current Opinion in Pulmonary Medicine 1998;4(4):220-5.
32. Holmstrom 1999 Holmstrom M, Aberg W, Lockner D, Paul C. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: A retrospective analysis. Thrombosis & Haemostasis 1999;82(4):1222-6.
33. Jahanzeb 2005 Jahanzeb M, Jahanzeb M. Management of deep vein thrombosis in cancer patients. Journal of the Nation Comprehensive Cancer Network 2005;3(Suppl 1):S50-3.
34. Leizorovicz 1994 Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994;309(6950):299-304.
35. Levine 2001 Levine MN. Management of thromboembolic disease in cancer patients. Haemostasis 2001;31(Suppl 1):68-9.
36. Martin-Carbonero2002 Martin-Carbonero L, Salgado X, Pedrajas JM, Armengol JG, Jimenez Rodriguez-Madridejos R, Fernandez-Cruz A. Short-term and long-term evolution of deep vein thrombosis treated by a health care unit. Revista Clinica Espanola 2002;202(8):430-4.
37. Menzoian 1983 Menzoian JO, Sequeira JC, Doyle JE, Cantelmo NL, Nowak M, Tracey K, et al.Therapeutic and clinical course of deep vein thrombosis. American Journal of Surgery 1983;146(5):581-5.
38. Naschitz 1994 Naschitz JE. Thromboembolism in cancer: changing trends. Radiology 1994;19:2.
39. Prandoni 1988 Prandoni P, Vigo M, Tropeano PF, Carletti E, Corbetti F, Antonello G, et al.Treatment of venous thromboembolic disease using low molecular weight CY216 heparin in patients with high risk of hemorrhage. Annali Italiani di Medicina Interna 1988;3(3):213-9.
40. Prandoni 1990 Prandoni P, Vigo M, Cattelan AM, Ruol A. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216). Haemostasis 1990;20(Suppl 1):220-3.
41. Prandoni 2005 Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005;106(13):4027-33.
42. Sakuragi 2003 Sakuragi T, Sakao Y, Furukawa K, Rititake K, Ohtsubo S, Okazaki Y, et al.Successful management of acute pulmonary embolism after surgery for lung cancer. European Journal Of Cardio-Thoracic Surgery 2003;24(4):580-7.
43. Siragusa 2005 Siragusa S, Arcara C, Malato A, Anastasio R, Valerio MR, Fulfaro F, et al.Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Annals of Oncology 2005;16(Suppl 4):iv136-iv139.
44. Turchetti 2003 Turchetti V, Bellini MA, Richichi MG, Boschi L, Postorino G, Naddeo S, et al.Venous thrombosis in the elderly: Pathogenesis, diagnosis, treatment and follow-up. Giornale di Gerontologia 2003;51(4):212-8.
45. Warkentin 1995 Warkentin T.Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New England Journal of Medicine 1995;332:1330-6.
46. Wong 2003 Wong JEL. Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE. Cancer Treatment Reviews 2003;29:11-3.
47. Albada 1989 Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 1989;80(4):935-40.
48. Belcaro 1999 Belcaro G, Nicolaides AN, Cesarone MR, Laurora G, De Sanctis MT, Incandela L. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology 1999;50(10):781-7.
49. Bratt 1990 Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thrombosis & Haemostasis 1990;64(4):506-10.
50. Buller 2004 Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F et al Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine 2004;140(11):867-73.
51. Fiessinger 1996 Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, et al.Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis & Haemostasis 1996;76(2):195-9.
52. Harenberg 2000 Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Buller HR. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis & Haemostasis 2000;83(5):652-6.
53. Harenberg 1990 Harenberg J, Huck K, Bratsch H, Stehle G, Dempfle CE, Mall K, et al.Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis 1990;20(Suppl 1):205-19.
54. Holm 1986 Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, et al.Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16(Suppl 2):30-7.
55. Hull 2000 Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al.Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.American-Canadian Thrombosis Study Group. Archives of Internal Medicine 2000;160(2):229-36.
56. Luomanmaki 1996 Loumanmaki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine 1996;240(2):85-92.
57. Riess 2003 Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Grave M, Patek F, et al.Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis & Haemostasis 2003;90(2):252-9.
58. Akl 2007a Akl EA, Kamath G, Kim SY, Yosuico V, Barba M, Terrenato I, et al.Oral anticoagulation for prolonging survival in patients with cancer. Cochrane Database of Systematic Reviews 2007, Issue (2) Art. No.: CD006466. DOI: 10.1002/14651858.CD006466.Art. No.: CD006466. DOI:10.1002/14651858.CD006466.
59. Akl 2007b Akl EA, vanDoormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, et al.Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database of Systematic Reviews 2007, Issue 3 Art. No.: CD006652. DOI: 10.1002/14651858.CD006652.Art. No.: CD006652. DOI: 10.1002/14651858.CD006652.
60. Dolovich 2000 Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Archives of Internal Medicine 2000;160(2):181-8.
61. Duval 2000 Duval SJ, Tweedie RL. Trim and fill: A simple funnel plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:276-84.
62. Gallus 1997 Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thrombosis And Haemostasis 1997;78(1):126-32.
63. Heit 2000 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Archives of Internal Medicine 2000;160(6):809-15.
64. Hettiarachchi 1999 Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thrombosis & Haemostasis 1999;82:947-52.
65. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-560.
66. Hutten 2000 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. Journal of Clinical Oncology 2000;18(17):3078-83.
67. Kakkar 1970 Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a "high risk" group?. American Journal of Surgery 1970;120(4):527-30.
68. Kakkar 2000 Kakkar AK, Breddin HK, Kakkar VV, Kadziola ZA. Treatment of deep vein thrombosis in cancer: A comparison of unfractionated and low molecular weight heparin. Blood 2000;96(11):449A-A.
69. Levitan 1999 Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R. Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data. Medicine 1999;78(5):285-91.
70. Oxman 2002 Oxman A, Guyatt G. When to believe a subgroup analysis. In: GuyattG, RennieD editor(s). Users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago: AMA Press, 2002: 553-65.
71. Pineo 1997 Pineo GF, Hull RD, Raskob GE, Brant RF, Green D. Decreased mortality in cancer patients treated for proximal deep vein thrombosis with low-molecular-weight heparin as compared with unfractionated heparin. Thrombosis And Haemostasis 1997;Suppl. S:O1566.
72. Prandoni 2002 Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al.Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484-88.
73. Quinlan 2004 Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism - A meta-analysis of randomized, controlled trials. Annals of Internal Medicine 2004;140(3):175-83.
74. Rodgers 1999 Rodgers GM, Spiro TE. Treatment of cancer-associated deep-vein thrombosis with enoxaparin: comparison with unfractionated heparin therapy (Meeting abstract). Proceedings of the American Association for Cancer Research. 1999.
75. Siragusa 1996 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. American Journal of Medicine 1996;100(3):269-77.
76. Sorensen 2002 Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. New England Journal Of Medicine 2000;343(25):1846-50.
77. van Dongen 2007 vanDongen CJJ, van den Belt AGM, Prins MH, Lensing AWA. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2004, Issue 4 . Art. No.: CD001100. DOI: 10.1002/14651858.CD001100.pub2.Art. No.: CD001100. DOI:10.1002/14651858. CD001100.pub2.